Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Breast Cancer

Free Subscription Articles published in Breast Cancer Res Retrieve available abstracts of 152 articles: HTML format Text format

Single Articles

March 2010
1. LI J , Eriksson L, Humphreys K, Czene K, et al
   Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer.
   Breast Cancer Res. 2010;12:R19.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. HU Z , Huang G, Sadanandam A, Gu S, et al
   The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.
   Breast Cancer Res. 2010;12:R18.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. ASAKAWA H , Koizumi H, Koike A, Takahashi M, et al
   Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
   Breast Cancer Res. 2010;12:R17.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. KLAWITTER J , Shokati T, Moll V, Christians U, et al
   Effects of lovastatin on breast cancer cells: a proteo-metabonomic study.
   Breast Cancer Res. 2010;12:R16.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. CRONIN-FENTON DP , Pedersen L, Lash TL, Friis S, et al
   Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study.
   Breast Cancer Res. 2010;12:R15.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
6. STEPHANSSON O , Granath F, Ekbom A, Michels KB, et al
   Risk of breast cancer among daughters of mothers with diabetes: a population-based cohort study.
   Breast Cancer Res. 2010;12:R14.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. LAGADEC C , Vlashi E, Della Donna L, Meng Y, et al
   Survival, self-renewing capacity and multi-lineage potency of breast cancer initiating cells during fractionated radiation treatment.
   Breast Cancer Res. 2010;12:R13.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. MAVADDAT N , Pharoah PD, Blows F, Driver KE, et al
   Familial relative risks for breast cancer by pathological subtype: a population-based cohort study.
   Breast Cancer Res. 2010;12:R10.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. SCOTT RJ
   Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?
   Breast Cancer Res. 2010;12:102.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. ZECCHIN D , Bardelli A
    Tracking the genomic evolution of breast cancer metastasis.
    Breast Cancer Res. 2010;12:302.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2010
11. LIU B , Han M, Sun RH, Wang JJ, et al
    ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation.
    Breast Cancer Res. 2010;12:R9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. LUO T , Wang J, Yin Y, Hua H, et al
    (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma.
    Breast Cancer Res. 2010;12:R8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. AAROE J , Lindahl T, Dumeaux V, Saebo S, et al
    Gene expression profiling of peripheral blood cells for early detection of breast cancer.
    Breast Cancer Res. 2010;12:R7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. SUN Y , Turbin D, Ling K, Thapa N, et al
    Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer.
    Breast Cancer Res. 2010;12:R6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. MARSHALL SF , Clarke CA, Deapen D, Delellis Henderson K, et al
    Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort.
    Breast Cancer Res. 2010;12:R4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. MUGGERUD AA , Ronneberg JA, Warnberg F, Botling J, et al
    Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer.
    Breast Cancer Res. 2010;12:R3.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. TAM CY , Martin LJ, Hislop G, Hanley AJ, et al
    Risk factors for breast cancer in postmenopausal Caucasian and Chinese-Canadian women.
    Breast Cancer Res. 2010;12:R2.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. WISHART GC , Azzato EM, Greenberg DC, Rashbass J, et al
    PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.
    Breast Cancer Res. 2010;12:R1.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2009
19. MARUTI SS , Ulrich CM, Jupe ER, White E, et al
    MTHFR C677T and postmenopausal breast cancer risk by intakes of one-carbon metabolism nutrients: a nested case-control study.
    Breast Cancer Res. 2009;11:R91.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. SCHMIDT MK , Tommiska J, Broeks A, van Leeuwen FE, et al
    Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Breast Cancer Res. 2009;11:R89.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. MAIA AT , Spiteri I, Lee AJ, O'Reilly M, et al
    Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast.
    Breast Cancer Res. 2009;11:R88.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. MELCHOR L , Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM, et al
    Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes.
    Breast Cancer Res. 2009;11:R86.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. SUTHERLAND RL , Musgrove EA
    CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease.
    Breast Cancer Res. 2009;11:112.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2009
24. KALLERGI G , Markomanolaki H, Giannoukaraki V, Papadaki MA, et al
    Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.
    Breast Cancer Res. 2009;11:R84.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. NOLENS G , Pignon JC, Koopmansch B, Elmoualij B, et al
    Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.
    Breast Cancer Res. 2009;11:R83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. MEYER MJ , Fleming JM, Ali MA, Pesesky M, et al
    Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines.
    Breast Cancer Res. 2009;11:R82.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. THOMPSON DJ , Leach MO, Kwan-Lim G, Gayther SA, et al
    Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study.
    Breast Cancer Res. 2009;11:R80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. TOMASKOVIC-CROOK E , Thompson EW, Thiery JP
    Epithelial to mesenchymal transition and breast cancer.
    Breast Cancer Res. 2009;11:213.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. HARTMAN J , Lam EW, Gustafsson JA, Strom A, et al
    Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation.
    Breast Cancer Res. 2009;11:R79.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. INBAR-ROZENSAL D , Castiel A, Visochek L, Castel D, et al
    A selective eradication of human non-hereditary breast cancer cells by phenanthridine derived polyADP-ribose polymerase inhibitors.
    Breast Cancer Res. 2009;11:R78.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
31. KESISIS G , Makris A, Miles D
    Update on the use of aromatase inhibitors in early-stage breast cancer.
    Breast Cancer Res. 2009;11:211.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. NEUHAUSEN SL , Brummel S, Ding YC, Singer CF, et al
    Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
    Breast Cancer Res. 2009;11:R76.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. HSIEH SM , Look MP, Sieuwerts AM, Foekens JA, et al
    Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.
    Breast Cancer Res. 2009;11:R75.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. AGYIN JK , Santhamma B, Nair HB, Roy SS, et al
    BU-32: a novel proteasome inhibitor for breast cancer.
    Breast Cancer Res. 2009;11:R74.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. SCHMITT M , Foekens JA
    Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells.
    Breast Cancer Res. 2009;11:109.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. PEGRAM MD , Borges V, Ibrahim N, Fuloria J, et al
    Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
    Breast Cancer Res. 2009;11:R73.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
37. WHYTE J , Bergin O, Bianchi A, McNally S, et al
    Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.
    Breast Cancer Res. 2009;11:209.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. WICHA MS
    Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.
    Breast Cancer Res. 2009;11:108.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. SCHWARZENBACH H , Pantel K, Kemper B, Beeger C, et al
    Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
    Breast Cancer Res. 2009;11:R71.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. WORKMAN HC , Miller JK, Ingalla EQ, Kaur RP, et al
    The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells.
    Breast Cancer Res. 2009;11:R70.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. DARB-ESFAHANI S , Loibl S, Muller BM, Roller M, et al
    Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Breast Cancer Res. 2009;11:R69.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. YAN Y , Skliris G, Penner C, Chooniedass-Kothari S, et al
    Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients.
    Breast Cancer Res. 2009;11:R67.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. OGUNLEYE AA , Holmes MD
    Physical activity and breast cancer survival.
    Breast Cancer Res. 2009;11:106.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
44. MCCULLOUGH ML , Stevens VL, Patel R, Jacobs EJ, et al
    Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort.
    Breast Cancer Res. 2009;11:R64.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. MILES DW
    Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2009;11:208.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. PICKARD MR , Green AR, Ellis IO, Caldas C, et al
    Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer.
    Breast Cancer Res. 2009;11:R60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. FEHM T , Hoffmann O, Aktas B, Becker S, et al
    Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by reverse-transcriptase polymerase chain reaction and comparison to status of bone marrow disseminated cells.
    Breast Cancer Res. 2009;11:R59.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. FASSAN M , Baffa R, Palazzo JP, Lloyd J, et al
    MicroRNA expression profiling of male breast cancer.
    Breast Cancer Res. 2009;11:R58.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. HAN J , Ma I, Hendzel MJ, Allalunis-Turner J, et al
    The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
    Breast Cancer Res. 2009;11:R57.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
50. ROY LD , Pathangey LB, Tinder TL, Schettini JL, et al
    Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
    Breast Cancer Res. 2009;11:R56.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. COLLU GM , Meurette O, Brennan K
    Is there more to Wnt signalling in breast cancer than stabilisation of beta-catenin?
    Breast Cancer Res. 2009;11:105.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. BILD AH , Parker JS, Gustafson AM, Acharya CR, et al
    An integration of complementary strategies for gene expression analysis to reveal novel therapeutic opportunities for breast cancer.
    Breast Cancer Res. 2009;11:R55.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. BOLLET MA , Savignoni A, De Koning L, Tran Perennou C, et al
    Tumour aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.
    Breast Cancer Res. 2009;11:R54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
54. TRUJILLO MA , Oneal MJ, Davydova J, Bergert E, et al
    Construction of a MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for gene therapy of breast cancer.
    Breast Cancer Res. 2009;11:R53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
55. BERNACIAK TM , Zareno J, Parsons JT, Silva CM, et al
    A novel role for Signal Transducer and Activator of Transcription 5b (STAT5b) in beta1 integrin-mediated human breast cancer cell migration.
    Breast Cancer Res. 2009;11:R52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. SASSEN A , Diermeier-Daucher S, Sieben M, Ortmann O, et al
    Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
    Breast Cancer Res. 2009;11:R50.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. EPPLEIN M , Shvetsov YB, Wilkens LR, Franke AA, et al
    Plasma carotenoids, retinol, and tocopherols and postmenopausal breast cancer risk in the Multiethnic Cohort Study: a nested case-control study.
    Breast Cancer Res. 2009;11:R49.
    PubMed     Text format     Related articles    Abstract available
    
    
    
58. MORROW PK , Zambrana F, Esteva FJ
    Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res. 2009;11:207.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. AKTAS B , Tewes M, Fehm T, Hauch S, et al
    Stem cell and epithelial-mesenchymal transition markers are frequently over-expressed in circulating tumor cells of metastatic breast cancer patients.
    Breast Cancer Res. 2009;11:R46.
    PubMed     Text format     Related articles    Abstract available
    
    
    
60. KALAGER M , Haldorsen T, Bretthauer M, Hoff G, et al
    Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study.
    Breast Cancer Res. 2009;11:R44.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
61. LIEBERTHAL JG , Kaminsky M, Parkhurst CN, Tanese N, et al
    The role of YY1 in reduced HP1 alpha gene expression in invasive human breast cancer cells.
    Breast Cancer Res. 2009;11:R42.
    PubMed     Text format     Related articles    Abstract available
    
    
    
62. FOSTER FM , Owens TW, Tanianis-Hughes J, Clarke RB, et al
    Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
    Breast Cancer Res. 2009;11:R41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
63. ALBERGARIA A , Paredes J, Sousa B, Milanezi F, et al
    Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
    Breast Cancer Res. 2009;11:R40.
    PubMed     Text format     Related articles    Abstract available
    
    
    
64. ALIX-PANABIERES C , Vendrell JP, Slijper M, Pelle O, et al
    Full length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.
    Breast Cancer Res. 2009;11:R39.
    PubMed     Text format     Related articles    Abstract available
    
    
    
65. KONINKI K , Tanner M, Auvinen A, Isola J, et al
    HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.
    Breast Cancer Res. 2009;11:R37.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. GONZALEZ RR , Watters A, Xu Y, Singh UP, et al
    Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.
    Breast Cancer Res. 2009;11:R36.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. MARKOPOULOS C , Dafni U, Misitzis J, Zobolas V, et al
    Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid sub-study.
    Breast Cancer Res. 2009;11:R35.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. WIESMANN F , Veeck J, Galm O, Hartmann A, et al
    Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.
    Breast Cancer Res. 2009;11:R34.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
69. MATSUDA Y , Schlange T, Oakeley EJ, Boulay A, et al
    WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth.
    Breast Cancer Res. 2009;11:R32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
70. KWAN ML , Kushi LH, Weltzien E, Maring B, et al
    Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.
    Breast Cancer Res. 2009;11:R31.
    PubMed     Text format     Related articles    Abstract available
    
    
    
71. CZENE K , Reilly M, Hall P, Hartman M, et al
    A constant risk of familial breast cancer? A population-based family study.
    Breast Cancer Res. 2009;11:R30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
72. INCASSATI A , Pinderhughes A, Eelkema R, Cowin P, et al
    Links between transforming growth factor-beta and canonical Wnt signaling yield new insights into breast cancer susceptibility, suppression and tumor heterogeneity.
    Breast Cancer Res. 2009;11:103.
    PubMed     Text format     Related articles    Abstract available
    
    
    
73. LJUSLINDER I , Golovleva I, Henriksson R, Grankvist K, et al
    Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer.
    Breast Cancer Res. 2009;11:403.
    PubMed     Text format     Related articles   
    
    
    
74. LOWERY AJ , Miller N, Devaney A, McNeill RE, et al
    MicroRNA signatures predict estrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Breast Cancer Res. 2009;11:R27.
    PubMed     Text format     Related articles    Abstract available
    
    
    
75. WILLIAMS C , Helguero L, Edvardsson K, Haldosen LA, et al
    Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression.
    Breast Cancer Res. 2009;11:R26.
    PubMed     Text format     Related articles    Abstract available
    
    
    
76. KALRA J , Warburton C, Fang K, Edwards L, et al
    QLT0267, a small molecule inhibitor targeting Integrin-Linked Kinase (ILK), and Docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment out
    Breast Cancer Res. 2009;11:R25.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
77. HANCOX RA , Allen MD, Holliday DL, Edwards DR, et al
    Tumor-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms.
    Breast Cancer Res. 2009;11:R24.
    PubMed     Text format     Related articles    Abstract available
    
    
    
78. JACQUEMIER J , Charafe-Jauffret E, Monville F, Esterni B, et al
    Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly pronostic in luminal breast cancer.
    Breast Cancer Res. 2009;11:R23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
79. KIM BK , Lee JW, Park PJ, Shin YS, et al
    The multiplex bead array approach to identifying serum biomarkers associated with breast cancer.
    Breast Cancer Res. 2009;11:R22.
    PubMed     Text format     Related articles    Abstract available
    
    
    
80. OAKMAN C , Bessi S, Zafarana E, Galardi F, et al
    Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer.
    Breast Cancer Res. 2009;11:205.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
81. TESCHENDORFF AE , Caldas C
    The breast cancer somatic 'muta-ome': tackling the complexity.
    Breast Cancer Res. 2009;11:301.
    PubMed     Text format     Related articles    Abstract available
    
    
    
82. SCHEDIN P , Borges V
    Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer.
    Breast Cancer Res. 2009;11:102.
    PubMed     Text format     Related articles    Abstract available
    
    
    
83. KOURTIDIS A , Srinivasaiah R, Carkner RD, Brosnan MJ, et al
    PPARgamma protects ERBB2-positive breast cancer cells from palmitate toxicity.
    Breast Cancer Res. 2009;11:R16.
    PubMed     Text format     Related articles    Abstract available
    
    
    
84. LOPEZ-TARRUELLA S , Martin M
    Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer.
    Breast Cancer Res. 2009;11:204.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
85. TOMMASI S , Karm DL, Wu X, Yen Y, et al
    Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer.
    Breast Cancer Res. 2009;11:R14.
    PubMed     Text format     Related articles    Abstract available
    
    
    
86. SCHNITT SJ
    The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin.
    Breast Cancer Res. 2009;11:101.
    PubMed     Text format     Related articles    Abstract available
    
    
    
87. BARCELLOS-HOFF MH , Akhurst RJ
    Transforming growth factor-beta in breast cancer: too much, too late.
    Breast Cancer Res. 2009;11:202.
    PubMed     Text format     Related articles    Abstract available
    
    
    
88. EISELER T , Doeppler H, Yan IK, Goodison S, et al
    Protein Kinase D1 regulates MMP expression and inhibits breast cancer cell invasion.
    Breast Cancer Res. 2009;11:R13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
89. NAKAYAMA S , Torikoshi Y, Takahashi T, Yoshida T, et al
    Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
    Breast Cancer Res. 2009;11:R12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
90. FROGNE T , Laenkholm AV, Lyng MB, Henriksen KL, et al
    Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor positive tumors.
    Breast Cancer Res. 2009;11:R11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
91. WOOLCOTT CG , Maskarinec G, Haiman CA, Verheus M, et al
    The association between breast cancer susceptibility loci and mammographic density: the Multiethnic Cohort.
    Breast Cancer Res. 2009;11:R10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
92. ZELL JA , Tsang WY, Taylor TH, Mehta RS, et al
    Prognostic impact of HER2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2014 IBC patient cases from the California Cancer Registry.
    Breast Cancer Res. 2009;11:R9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
93. MA XJ , Dahiya S, Richardson EA, Erlander M, et al
    Gene expression profiling of tumor microenvironment during breast cancer progression.
    Breast Cancer Res. 2009;11:R7.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
94. WEBER G , Chamorro CI, Granath F, Liljegren A, et al
    Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer.
    Breast Cancer Res. 2009;11:R6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
95. TAN BK , Lim GH, Czene K, Hall P, et al
    Do Asian breast cancer patients have poorer survival than their Western counterparts? A comparison between Singapore and Stockholm.
    Breast Cancer Res. 2009;11:R4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
96. HOLLIDAY DL , Brouilette KT, Markert A, Gordon LA, et al
    Novel multicellular organotypic models of normal and malignant breast: tools for dissecting the role of the microenvironment in breast cancer progression.
    Breast Cancer Res. 2009;11:R3.
    PubMed     Text format     Related articles    Abstract available
    
    
    
97. SNOJ N , Bedard PL, de Azambuja E, Cardoso F, et al
    Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
    Breast Cancer Res. 2009;11:201.
    PubMed     Text format     Related articles    Abstract available
    
    
    
98. NEUBAUER H , Clare SE, Wozny W, Schwall GP, et al
    Correction: Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
    Breast Cancer Res. 2009;11:401.
    PubMed     Text format     Related articles   
    
    
    
99. WELLS V , Mallucci L
    PI3K targeting by the beta-GBP cytokine negates akt gene expression and leads aggressive breast cancer cells to apoptotic death.
    Breast Cancer Res. 2009;11:R2.
    PubMed     Text format     Related articles    Abstract available
    
    
    
100. GOMEZ GARCIA EB , Oosterwijk JC, Timmermans M, van Asperen CJ, et al
     A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
     Breast Cancer Res. 2009;11:R8.
     PubMed     Text format     Related articles    Abstract available
     
     
     
101. 
     Latest advances in breast cancer. Abstracts of the VIII Madrid Breast Cancer Conference. Madrid, Spain. June 24-26, 2009.
     Breast Cancer Res. 2009;11 Suppl 1:P1-33.
     PubMed     Text format     Related articles   
     
     
     
102. TROESTER MA , Swift-Scanlan T
     Challenges in studying the etiology of breast cancer subtypes.
     Breast Cancer Res. 2009;11:104.
     PubMed     Text format     Related articles    Abstract available
     
     
     
103. CARRACEDO A , Egervari K, Salido M, Rojo F, et al
     FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors.
     Breast Cancer Res. 2009;11:402.
     PubMed     Text format     Related articles   
     
     
     
104. UNTCH M , von Minckwitz G
     Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents.
     Breast Cancer Res. 2009;11:203.
     PubMed     Text format     Related articles    Abstract available
     
     
     
105. STEAD LA , Lash TL, Sobieraj JE, Chi DD, et al
     Triple-negative breast cancers are increased in black women regardless of age or body mass index.
     Breast Cancer Res. 2009;11:R18.
     PubMed     Text format     Related articles    Abstract available
     
     
     
106. KULKARNI SA , Hicks DG, Watroba NL, Murekeyisoni C, et al
     TLE3 as a candidate biomarker of response to taxane therapy.
     Breast Cancer Res. 2009;11:R17.
     PubMed     Text format     Related articles    Abstract available
     
     
     
107. RODY A , Holtrich U, Pusztai L, Liedtke C, et al
     T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.
     Breast Cancer Res. 2009;11:R15.
     PubMed     Text format     Related articles    Abstract available
     
     
     
108. ELLIS P
     Recent advances in systemic therapy for breast cancer: new technologies for a new era.
     Breast Cancer Res. 2009;11:107.
     PubMed     Text format     Related articles   
     
     
     
109. DARBRE PD
     Underarm antiperspirants/deodorants and breast cancer.
     Breast Cancer Res. 2009;11 Suppl 3:S5.
     PubMed     Text format     Related articles   
     
     
     
110. BOYLE P , Boffetta P
     Alcohol consumption and breast cancer risk.
     Breast Cancer Res. 2009;11 Suppl 3:S3.
     PubMed     Text format     Related articles   
     
     
     
111. DI COSIMO S
     Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.
     Breast Cancer Res. 2009;11 Suppl 3:S25.
     PubMed     Text format     Related articles   
     
     
     
112. CLARKE R
     The role of preclinical animal models in breast cancer drug development.
     Breast Cancer Res. 2009;11 Suppl 3:S22.
     PubMed     Text format     Related articles   
     
     
     
113. WISHART GC , Chetty U
     Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
     Breast Cancer Res. 2009;11 Suppl 3:S17.
     PubMed     Text format     Related articles   
     
     
     
114. RAGAZ J
     Radiation impact in breast cancer.
     Breast Cancer Res. 2009;11 Suppl 3:S14.
     PubMed     Text format     Related articles   
     
     
     
115. PUSZTAI L
     Gene expression profiling of breast cancer.
     Breast Cancer Res. 2009;11 Suppl 3:S11.
     PubMed     Text format     Related articles   
     
     
     
116. MILLER WR
     Controversies in breast cancer 2009.
     Breast Cancer Res. 2009;11 Suppl 3:S1.
     PubMed     Text format     Related articles   
     
     
     December 2008
117. VAUGHT D , Brantley-Sieders DM, Chen J
     Eph receptors in breast cancer: roles in tumor promotion and tumor suppression.
     Breast Cancer Res. 2008;10:217.
     PubMed     Text format     Related articles    Abstract available
     
     
     January 2008
118. CAMERON DA
     Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against.
     Breast Cancer Res. 2008;10 Suppl 4:S8.
     PubMed     Text format     Related articles   
     
     
     
119. DIXON JM , Montgomery DA
     Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for.
     Breast Cancer Res. 2008;10 Suppl 4:S7.
     PubMed     Text format     Related articles   
     
     
     
120. FALLOWFIELD L , George D
     Introduction to the sessions on 'Debate: extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors'.
     Breast Cancer Res. 2008;10 Suppl 4:S6.
     PubMed     Text format     Related articles   
     
     
     
121. ALLRED DC
     The utility of conventional and molecular pathology in managing breast cancer.
     Breast Cancer Res. 2008;10 Suppl 4:S4.
     PubMed     Text format     Related articles   
     
     
     
122. TABAR L , Dean PB
     Thirty years of experience with mammography screening: a new approach to the diagnosis and treatment of breast cancer.
     Breast Cancer Res. 2008;10 Suppl 4:S3.
     PubMed     Text format     Related articles   
     
     
     
123. INGLE JN
     Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer.
     Breast Cancer Res. 2008;10 Suppl 4:S17.
     PubMed     Text format     Related articles   
     
     
     
124. CUZICK J
     Assessing risk for breast cancer.
     Breast Cancer Res. 2008;10 Suppl 4:S13.
     PubMed     Text format     Related articles   
     
     
     
125. ECCLES DM
     Identification of personal risk of breast cancer: genetics.
     Breast Cancer Res. 2008;10 Suppl 4:S12.
     PubMed     Text format     Related articles   
     
     
     
126. HOWELL A , Harvie M
     Should lifestyle modifications be promoted to prevent breast cancer?
     Breast Cancer Res. 2008;10 Suppl 4:S11.
     PubMed     Text format     Related articles   
     
     
     
127. SANTEN RJ
     Assessing individual risk for breast cancer: role of oestrogens and androgens.
     Breast Cancer Res. 2008;10 Suppl 4:S10.
     PubMed     Text format     Related articles   
     
     
     
128. MILLER WR
     Controversies in Breast Cancer 2008.
     Breast Cancer Res. 2008;10 Suppl 4:S1.
     PubMed     Text format     Related articles   
     
     
     
129. 
     Abstracts of Symposium Mammographicum 2008. July 6-8, 2008. Lille, France.
     Breast Cancer Res. 2008;10 Suppl 3:P1-88.
     PubMed     Text format     Related articles   
     
     
     
130. CAO D , Polyak K, Halushka MK, Nassar H, et al
     Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9.
     Breast Cancer Res. 2008;10:R91.
     PubMed     Text format     Related articles    Abstract available
     
     
     
131. GEBAUER G
     On the way to specifically targeting minimal residual disease?
     Breast Cancer Res. 2008;10:112.
     PubMed     Text format     Related articles    Abstract available
     
     
     
132. CASTRO NP , Osorio CA, Torres C, Bastos EP, et al
     Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
     Breast Cancer Res. 2008;10:R87.
     PubMed     Text format     Related articles    Abstract available
     
     
     
133. DEMICHELI R , Biganzoli E, Boracchi P, Greco M, et al
     Recurrence dynamics does not depend on the recurrence site.
     Breast Cancer Res. 2008;10:R83.
     PubMed     Text format     Related articles    Abstract available
     
     
     
134. BHARGAVA R , Dabbs DJ
     Luminal B breast tumors are not HER2 positive.
     Breast Cancer Res. 2008;10:404.
     PubMed     Text format     Related articles   
     
     
     
135. NEVEN P , Van Gorp T, Deraedt K
     A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis.
     Breast Cancer Res. 2008;10:109.
     PubMed     Text format     Related articles    Abstract available
     
     
     
136. HERSCHKOWITZ JI , He X, Fan C, Perou CM, et al
     The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.
     Breast Cancer Res. 2008;10:R75.
     PubMed     Text format     Related articles    Abstract available
     
     
     
137. 
     Proceedings of the Controversies in Breast Cancer 2008 meeting. September 1-2, 2008. Edinburgh, United Kingdom.
     Breast Cancer Res. 2008;10 Suppl 4:S1-26.
     PubMed     Text format     Related articles   
     
     
     
138. DOWSETT M
     Introduction to sessions on 'Predicting personal risk for breast cancer'.
     Breast Cancer Res. 2008;10 Suppl 4:S9.
     PubMed     Text format     Related articles   
     
     
     
139. MORROW M
     How much can improved molecular and pathologic discriminants change local therapy?
     Breast Cancer Res. 2008;10 Suppl 4:S5.
     PubMed     Text format     Related articles   
     
     
     
140. DOWSETT M
     Optimizing the implementation of future treatment using surrogate end-points.
     Breast Cancer Res. 2008;10 Suppl 4:S26.
     PubMed     Text format     Related articles   
     
     
     
141. GUIX M , Mayer IA, Meszoely IM, Arteaga CL, et al
     Evaluation of biological agents targeted at early-stage disease.
     Breast Cancer Res. 2008;10 Suppl 4:S25.
     PubMed     Text format     Related articles   
     
     
     
142. SMITH IE
     Neoadjuvant/presurgical treatments.
     Breast Cancer Res. 2008;10 Suppl 4:S24.
     PubMed     Text format     Related articles   
     
     
     
143. PRITCHARD KI
     Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?
     Breast Cancer Res. 2008;10 Suppl 4:S23.
     PubMed     Text format     Related articles   
     
     
     
144. LONNING PE
     Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.
     Breast Cancer Res. 2008;10 Suppl 4:S22.
     PubMed     Text format     Related articles    Abstract available
     
     
     
145. VERRILL M
     Introduction to sessions on 'Optimizing the implementation of future treatments--time to abandon traditional methods'.
     Breast Cancer Res. 2008;10 Suppl 4:S21.
     PubMed     Text format     Related articles   
     
     
     
146. JOHNSTON SR
     Integration of endocrine therapy with targeted agents.
     Breast Cancer Res. 2008;10 Suppl 4:S20.
     PubMed     Text format     Related articles   
     
     
     
147. DIXON JM , Morrow M
     Introduction to sessions on 'What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy'.
     Breast Cancer Res. 2008;10 Suppl 4:S2.
     PubMed     Text format     Related articles   
     
     
     
148. MILLER WR
     Identification and mechanisms of endocrine resistance.
     Breast Cancer Res. 2008;10 Suppl 4:S19.
     PubMed     Text format     Related articles   
     
     
     
149. HAYES DF
     Markers of endocrine sensitivity.
     Breast Cancer Res. 2008;10 Suppl 4:S18.
     PubMed     Text format     Related articles   
     
     
     
150. JORDAN VC , Patel R, Lewis-Wambi JS, Swaby RF, et al
     By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.
     Breast Cancer Res. 2008;10 Suppl 4:S16.
     PubMed     Text format     Related articles   
     
     
     
151. INGLE JN
     Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to'?
     Breast Cancer Res. 2008;10 Suppl 4:S15.
     PubMed     Text format     Related articles   
     
     
     
152. FALLOWFIELD L
     Psychosocial aspects of risk appraisal.
     Breast Cancer Res. 2008;10 Suppl 4:S14.
     PubMed     Text format     Related articles   
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: